Evaluation of novel targeting strategies to deliver engineered protein therapeutics in relevant in vitro and in vivo osteoarthritis models - Texts

Home
Main Navigation
Content
Search
Help

Font Standard Bold
Login

Research unit

INNOSUISSE

Project number

104.824.1 IP-LS

Project title

Evaluation of novel targeting strategies to deliver engineered protein therapeutics in relevant in vitro and in vivo osteoarthritis models

Texts for this project

	German	French	Italian	English
Short description		-	-
Abstract		-	-

Inserted texts

Category	Text
Short description (German)	Evaluation of novel targeting strategies to deliver engineered protein therapeutics in relevant in vitro and in vivo osteoarthritis models
Short description (English)	Evaluation of novel targeting strategies to deliver engineered protein therapeutics in relevant in vitro and in vivo osteoarthritis models
Abstract (German)	Osteoarthritis(OA) is a degenerative joint disease for which no disease-modifying drugs are available. Philochem AG and ETH Zurich will develop novel immunocytokines and evaluate delivery and screening systems to select the best candidate for the clinical development of a groundbreaking OA therapy.
Abstract (English)	Osteoarthritis(OA) is a degenerative joint disease for which no disease-modifying drugs are available. Philochem AG and ETH Zurich will develop novel immunocytokines and evaluate delivery and screening systems to select the best candidate for the clinical development of a groundbreaking OA therapy.